Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Pfizer abandons antibody for Duchenne
Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this
Latest news
-
Daily brief: Novartis spends big on ezcema,
Novartis eczema deal worth up to $1bn for biotechs. MorphoSys and Galapagos have signed a major new deal with Novartis on their atopic dermatitis candidate MOR106, an IL-17c antibody. ... The deal adds to MorphoSys’momentum, as it launched its listing
-
Roche starts new late-stage trials of Alzheimer’s candidate
In the interim, Roche and partner MorphoSys - which applied its antibody-generating technology to the creation of the drug - have been carrying out safety studies to ensure that hiking exposure to ... 2020. The decision to press ahead with the phase III
-
Janssen’s Tremfya cleared for European use
Tremfya, an anti-IL-23 monoclonal antibody, was developed using MorphoSys ’HuCAL antibody library technology, allowing the German biotech to collect royalties on Tremfya sales under a multiple target deal it ... Dr Simon Moroney, chief executive officer
-
Lilly and Boehringer combine breast cancer drugs in trial
BI 836845 is one of the drugs that has emerged from the company's long-standing antibody collaboration with MorphoSys, and is also being tested in combination with Novartis' Femara (exemestane)
-
Pfizer signs high-level deal with GPCR specialist Heptares
It also has collaborations in place with AstraZeneca (AZ), Merck &Co's Cubist unit, MorphoSys and Takeda.
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
-
Pharma deals during June 2014
Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Industry round up: appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
MorphoSys appoints Dr Markus Enzelberger as CSO. He succeeds Dr Marlies Sproll who resigns. ... German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team. She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Featured jobs
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Associate Director
-
£75, 000-90, 000
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Account Director
-
£48, 000 - £60, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Account Director
-
Excellent benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Medical Drones Market Global Industry Analysis, Trends and Forecast, 2017 – 2027
- Point Of Care Blood Testing Devices Market Growth and Forecast 2017 – 2027
- Deflectable Catheters Market Volume Analysis, size, share and Key Trends 2017 - 2027
- Humanized Mouse Model Market Expected to Expand at a Steady CAGR through 2027
- Pharmaceutical Intermediates Market Size, Analysis, and Forecast Report 2017 – 2027
- Cardiopulmonary Bypass System Market Revenue, Opportunity, Segment and Key Trends 2017 - 2027
PMHub
Weber Shandwick
At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...
Latest intelligence
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
- World Diabetes Day: Interaction and impact of diabetes on mental health
- For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
Quick links
Infographics
